📣We are super excited to share a preprint of our work with @Caldaslab on triple-negative breast cancer "avatars" #AbigailShea you rock! Great collaboration with Oscar M Rueda and #JeanAbraham, 🧵 Read below on @bioRxiv.👇

Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts biorxiv.org/content/10.110…

In triple-negative breast cancer, we have 👤 Developed an avatar platform predictive of patient's drug responses ➕ Modelled patient- and drug-specific tumour evolution 💊 Identified a novel mechanism of treatment response, underpinned by phenotypic plasticity

🎉🎉🎉Carlos will receive this year's Fondation ARC Leopold Griffuel Award, the most important prize in #CancerResearch in Europe! Amazing recognition of the contributions from all members of the lab and patients over the past 26 years! 🥹🥰 #bcsm Cancer Research UK CRUK Cambridge Institute Cambridge University

📣 Happy to share a preprint of our latest manuscript, available now in #bioRxiv. In this work we use #DNAbarcoding, #lineagetracing and #singlecell technologies to interrogate #plasticity and #cancerevolution in #neuroblastoma. We show that… 👇🧵 biorxiv.org/content/10.110…

🚀 Exciting Opportunity! 🚀 We're seeking passionate clinicians to join our Clinical PhD Fellowships at Alejandra Bruna Lab at the The ICR . Advance your career in cancer research, gain expertise, and make a significant impact. 🎓🔬

We developed a co-clinical trial platform for treatment-naïve triple-negative breast cancer. In vivo PDXs and ex vivo PDTCs were treated in parallel with patients. 💡 PDXs accurately mirrored clinical drug responses of their matched patient.

🧵 (2/3) We next tested PDX responses to alternative clinical trial arms and other relevant treatments. 💡These data suggest PDXs could be used as anticipatory tools. However, we also highlighted important considerations when using PDXs in this way.

🧵 (3/3) We then used the platform to study cancer evolution and showed: 💡permanent non-genetic phenotypic changes in response to Olaparib. 💡tumours undergo treatment-specific functional changes. Importantly, some of these changes affected responses to next-line treatments.

❤️ Thank you to the patients who donated to this research, our research institutes and funders. This research was conducted in CaldasLab and Alejandra Bruna Lab at CRUK Cambridge Institute, MRC Biostatistics Unit, Cambridge University and The ICR.

CaldasLab CRUK Cambridge Institute MRC Biostatistics Unit Cambridge University The ICR Big shout out to AMAZING Abby, a force of nature that drove this research forward despite many drawbacks. You are a super star! HUGE CONGRATULATIONS Abigail Shea.

It was a collaborative effort led by Alejandra Bruna Lab, Oscar M Rueda, Jean Abraham & Carlos Caldas 🇵🇹🇪🇺🇬🇧🎗.

Thrilled to share our latest publication, out now in Cancer Research. A huge collaborative effort during my PhD in CaldasLab. A big thanks to everyone involved!